摩根大通-恒瑞医药(600276)2025财年创新药增长稳健,丰富管线与BD潜力驱动全创新驱动销售增长-Hengrui:Solid innovative drug growth in FY25;rich pipeline&BD potential to fuel full innovation-led sales growth-20261027【13页】

发表回复

后才能评论